Shinichi Sato Email

VP – Hisamitsu Group Strategy & Planning . Noven Pharmaceuticals

The Crossings, FL

Location

s****@noven.com

Primary Email

LinkedIn

Current Roles

Employees:
1072
Revenue:
$211.7M
About
Noven Pharmaceuticals, Inc. (Nasdaq: NOVN), headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Our principal growth strategy is to apply our patented DOT Matrix® transdermal technology across diverse therapeutic categories with strong industry partners. Our patches are sold in over 30 countries, and a range of new prescription patches are under development. Together with Novartis Pharmaceuticals Corporation, we own Novogyne Pharmaceuticals, a successful women’s health products company with net sales of over $100 million in 2003. Novogyne’s lead product is Vivelle Dot® (estradiol transdermal system) – the smallest estrogen patch in the world and the most dispensed estrogen patch in the U.S. With the most advanced transdermal technology on the market, we are committed to expanding the universe of transdermal therapies for the benefit of patients, industry partners and shareholders.
Noven Pharmaceuticals Address
11960 SW 144th St
The Crossings, FL
United States
Noven Pharmaceuticals Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.